已出刊文章

【原著】探討Febuxostat於不同腎功能狀態下之療效、安全性與腎功能影響
Investigation of the Efficacy, Safety, and Renal Effects of Febuxostat across Different Levels of Renal Function
febuxostat、高尿酸血症、降尿酸治療、慢性腎臟病、腎臟保護、febuxostat, hyperuricemia, urate-lowering therapy, chronic kidney disease, renoprotection
周沁嫻 Chin-Hsien Chou1 、林宗萱 Tsung-Hsuan Lin2 、官玫秀 Mei-Hsiouh Guan1,*
1臺北市立聯合醫院忠孝院區藥劑科 、2奇美醫療財團法人奇美醫院藥劑部

摘要
目的:Febuxostat是一種廣泛使用的降尿酸藥物,目前相關研究對於其在嚴重腎功能不全者中的安全性與有效性尚無一致共識,且關於其潛在腎臟保護效果的相關討論亦逐漸增多。因此本研究旨在評估febuxostat於不同腎功能狀態患者之療效、安全性與腎功能影響,並探討其可能的腎臟保護趨勢。
方法:本研究為回溯性研究,納入2017年7月至2018年12月新使用febuxostat之門診患者,追蹤治療後第3與第6個月之血清尿酸(serum uric acid)、尿酸達標率與估算腎絲球過濾率(estimated glomerular filtration rate, eGFR)。依腎功能狀態進行分層分析,以評估febuxostat 對尿酸控制與腎功能變化之影響,亦分析初始每日劑量的分布及其對應之達標率。
結果:研究共納入213人。Febuxostat治療後,尿酸達標率於3個月顯著上升至75% (p < 0.001);於eGFR ≥30 與< 30 組,追蹤至6個月皆持續觀察到顯著尿酸下降與良好達標率。治療3個月後整體eGFR中位數及四分位距從38.59 (29.22–48.05) 上升至40.53 (27.99–53.96) mL/min/1.73 m2,僅在慢性腎臟病(chronic kidney disease, CKD),CKD 3b組有顯著差異(p = 0.002)。超過一半的病人起始劑量為80 mg/day,達標率高達87.9%,追蹤期間未發現與febuxostat 相關之不良反應紀錄。
結論:Febuxostat於各腎功能狀態下皆具良好降尿酸效果與高達標率,高劑量組之達標率相對較高,且整體耐受性良好;於中期腎功能不全患者中觀察到eGFR短期上升,顯示可能具有潛在腎臟保護效果。

ABSTRACT
Objective: Febuxostat is a widely used uric acid-lowering agent. Due to limited consensus on its safety and efficacy in severe renal impairment, and growing interest in its potential renoprotective effects, this study aimed to assess its efficacy, safety, and impact on renal function across renal function levels.
Methods: This retrospective study was conducted on outpatients who newly initiated febuxostat therapy from July 2017 to December 2018. Serum uric acid levels, target achievement rates, and estimated glomerular filtration rate (eGFR) were assessed at 3 and 6 months. Analyses were stratified by renal function to evaluate the effects of febuxostat on uric acid control and renal function. Additionally, the distribution of initial daily doses and their associated target achievement rates were analyzed.
Results: Among 213 patients, the urate target achievement rate significantly increased to 75% at 3 months (p < 0.001). Significant uric acid reductions and high target rates persisted at 6 months in both eGFR ≥30 and < 30 groups. Overall, median eGFR rose slightly from 38.59 (29.22–48.05) to 40.53 (27.99–53.96) mL/min/1.73 m2, with a significant increase observed only in the chronic kidney disease (CKD) stage 3b group (p = 0.002). Over half started on 80 mg/day, achieving an 87.9% target rate. No febuxostat-related adverse events were recorded during the follow-up.
Conclusion: Febuxostat demonstrated effective uric acid-lowering capacity and high target achievement rates across renal function levels, with higher target rates in the higher-dose group and good tolerance. A short-term increase in eGFR was observed in patients with stage 3b CKD, suggesting possible renoprotective potential.

Submitted for publication: 2025.11.28; Accepted for publication: 2026.04.06

操作進行中,請稍候~~~~
×
加载中...

系統通知

不再顯示此通知
×